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Active loading processwas encapsulated into liposomes in an attempt to increase its therapeutic index.
Loading of S12363 was achieved using two different processes based on the formation of either a pH gradient
or an ammonium gradient between the acidic inner liposomal compartment and the basic outer phase. High
encapsulation yields (N90%) were obtained using both processes for sphingomyelin/cholesterol/cholesterol-
PEG vesicles. Spectroﬂuorimetry measurements have shown that liposomes were characterized by an
internal pH around 4 for both loading processes. This internal pH was stable over a period of at least 20 days.
Differential scanning calorimetry coupled with time-resolved synchrotron X-ray diffraction was used to
study the drug/carrier supramolecular organization. In ammonium sulfate, S12363 was inserted into the
bilayer in the vicinity of the polar headgroup. In citrate buffer, S12363 was mainly adsorbed at the water–
lipid interface. The drug partitioning into the membrane was inhomogeneous and led to the formation of
drug-rich and drug-poor domains. This effect was enhanced in the presence of cholesterol, especially in
ammonium sulfate. To conclude, for both processes, the encapsulated drug was found inside the liposome
aqueous core but strongly interacting with the membrane.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Liposomes are simple lipid–bilayer vesicles useful as drug-delivery
systems. Liposomes were already suggested as drug carriers in cancer
chemotherapy by Gregoriadis et al. in 1974 [1]. Since then, their interest
in tumor treatment has increased tremendously. Indeed, the encapsula-
tion of anticancer drugswithin lipid vesicles has been shown to decrease
toxic side effects while increasing or maintaining therapeutic activity.
The drug substance S12363 is a vinca alkaloid derivative, synthesized by
grafting an optically active α-aminophosphonate on O4-deacetyl
vinblastine (Fig. 1) [2]. This compound was evaluated for cytotoxic anded cholesterol; DLS, dynamic
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ll rights reserved.antitumor activity against a spectrum of murine and human tumors and
was found to be on average 72 and 36 fold more cytotoxic than
vincristine and vinblastine respectively [3]. Unfortunately, this drug had
a very low therapeutic index, the efﬁcient dose being close to that of
toxicity; lethal dose 10 was 40 mg/kg in mouse. Therefore, S12363 was
encapsulated into long-circulating liposomes to take advantage of the so
called “Enhanced Permeability and Retention” (EPR) effect, and to
improve the therapeutic index of the compound [4,5].
The encapsulation procedure has been chosen on the basis of the
physico-chemical properties of the drug substance. Indeed, S12363 is
a weak base with a pH-dependent aqueous solubility and lipophilic
proﬁle. Thus, active loading process, based on the formation of either a
pH gradient [6] or an ammonium gradient [7] between the acidic
inner liposomal compartment and the basic outer phase, was used to
load S12363 into liposomes. Since the drug substance was highly
soluble in acidic medium and poorly soluble in a neutral/basic
environment, the drug accumulated inside the vesicles. Actually, high
encapsulation yields (N90%) were obtained using both gradients for
sphingomyelin/cholesterol/cholesterol-PEG (ESM/Chol/Chol-PEG)
vesicles composition. Liposomes formed with the encapsulated
S12363 drug were stable for weeks. The lipid–bilayer composition of
the liposome has been chosen for i) the high stability of ESM in acidic
conditions and ii) the property of Chol to condense ESM bilayers more
Fig. 1. Developed formula of sulfate S12363 or diethyle of (1S)-1-[(O4-deacetyl-3-
demethoxycarbonyl vincaleucoblastin-3-yl)-carbonylamino]-2-methyl propyl phos-
phonate (C51H72N5O10P, H2SO4). Molecular weight 1044.2 g/mol (946.144+98.078).
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lower permeability of such bilayers [9,10]. This bilayer composition
has been already used for similar drugs [11,12]. Furthermore,
pegylated cholesterol has been added to the liposomes bilayer to
obtain prolonged blood circulation of liposomes [4].
In such drug carrier the association between the drug and the lipid
vesicle is directly correlated with the encapsulation efﬁciency and
with the release proﬁle. Previous studies have found that the leakage
of S12363 from liposomes was mainly dependent upon the sample
dilution, a “burst effect” being observed in certain conditions [13].
Such phenomenon has not yet received interpretation but it is
suspected that the drug retention depends markedly on its interac-
tions with the liposomal membrane. Understanding the interactions
between the drug substance and the membrane bilayer is of prime
importance for the design of efﬁcient drug carrier vesicles because if
the release rate of the biologically active substance is more rapid than
the kinetic of tissue accumulation, then the therapeutic activity may
be compromised [4,14]. The detailed study of S12363 interactions with
lipids may lead to an improved design of liposome formulation for
most efﬁcient drug delivery.
The aim of this study was to identify the location of the S12363
drug substance into the liposome, depending on the loading
procedure used. In order to get this information, liposomal internal
pH has ﬁrst been measured by spectroﬂuorimetry measurements
using an appropriate pH probe and appearance of liposomes has
been studied by cryotransmission electron microscopy. Then,
phospholipid–drug molecular interactions have been investigated
by Differential scanning calorimetry (DSC) and by Small and Wide
Angle X-ray Diffraction (SWAXS) in medium corresponding to the
liposome formulation and using different lipid compositions. DSC is
a sensitive method to study the thermotropic phase behavior of lipid
membranes [9,15–17] and any interaction between the S12363 drug
and the bilayer modeling liposome membrane, would lead to a
modiﬁcation of the thermodynamic parameters (temperature of the
melting transition Tm and corresponding fusion enthalpy ΔH). The
structural parameters would also be modiﬁed by the drug/
membrane interactions thus X-ray diffraction provides complemen-
tary information [18,19].
2. Materials and methods
2.1. Materials
S12363 sulfate was obtained from the Institut de Recherche Servier
(IDRS, Suresnes, France), S12363 citrate and its corresponding base
were obtained from Technologie Servier (TES, Orléans, France). Egg
sphingomyelin (ESM) was purchased from Avanti Polar Lipids(Alabaster, AL, USA), cholesterol (Chol) from Sigma (St. Louis, MO,
USA) and pegylated cholesterol (Chol-PEG5000) from Nof Corporation
(Japan). Oregon Green (OrG) was obtained from Invitrogen (Cergy
Pontoise, France). The ESM utilized was highly enriched in long-chain
saturated fatty acids, particularly in 16:0 (84%) and contained only
small amounts of 18:0 (6%), 20:0 (2%), 22:0 (4%) and 24:0 (4%).
Puriﬁed water was used for sample and buffer preparations.
2.2. Liposome preparation and S12363 encapsulation
ESM, Chol and Chol-PEG5000 (50:45:5 molar ratio) were dissolved
and mixed in ter-butanol at 60 °C and then freeze-dried (CRIST,
Bioblock Scientiﬁc). The lyophilized mixture was hydrated with either
citrate buffer 200 mM pH 3 (pH gradient) or ammonium sulfate
155 mM pH 5.2 (ammonium gradient) and heated at 60 °C during
20 min. The suspension was subjected to ﬁve freeze–thaw cycles. The
resulting MLVs were then extruded through a Lipex® extrusion device
(Northern Lipids) equilibrated at 60 °C and under nitrogen pressure.
The extruder was ﬁtted with polycarbonate ﬁlters with successive
pore size of 0.8 μm, 0.4 μm, 0.2 μm and 0.1 μm. Resulting LUVs mean
diameter was estimated by quasi-elastic light scattering (Nanophox,
Sympatec) using the “unimodal” method of data processing. In the
case of pH gradient, LUVs were incubated with S12363 and
the gradient was formed by adding TRIS buffer and by increasing the
external pH of the citrate buffer to 6.8 with NaOH. The suspensionwas
mixed for 30 min at room temperature and 5 min at 70 °C. Finally, the
external pH was increase to 8 and a dilution was realized to have an
iso-osmotic suspension. To create the ammonium gradient, liposomes
were passed through a Hi-Prep desalting column pre-equilibrated
with glucose 5% in order to remove external sulfate ammonium salts.
S12363 was incubated with LUVs at room temperature for 15 min and
then at 60 °C for 20 min. The pH was ﬁxed at 6. The encapsulation
efﬁciency was determined by separating the entrapped drug from the
free by a gel exclusion chromatography through a Sephadex G75
column pre-equilibrated with the corresponding medium (citrate
buffer+TRIS buffer pH 8 or Glucose 5%). S12363 was followed by UV
spectroscopy at 230 nm. The dosage of the encapsulated fraction was
done by HPLC and the drug/phospholipid weight ratio was 1:35. The
rate of liposome drug uptake was more than 90% in both cases and
formulations were stable at 4 °C for at least 1 month.
2.3. Spectroﬂuorimetry measurements
In order to determine the pH of liposome core, a pH probe Oregon
Green (OrG) was encapsulated [20]. The OrG pH probewas solubilized
in the appropriate medium (citrate buffer or ammonium sulfate
solution) at 10−4 M before lipid hydration. Then, liposomes were
formed as described in previous section. Liposomes were separated
from free OrG by gel exclusion chromatography on Sephadex® G50
150–100 G (Sigma). The system was composed of a peristaltic pump
(Pharmacia LKB-Pump P-1), a six-way PTFE injection valve (Rheo-
dyne, type 50, Interchim, France), a 0.5 ml injection loop (Daka Ware,
Chicago, USA), a glass column (height=27 cm, DIAMETER=1 cm)
containing the gel swollen in the appropriate buffer, a 10 μl circulation
quartz cuvette (no. 010, Hellma, Germany) and a fraction collector
(Microcol, Gilson TDC80, Villiers le Bel, France). Elution was carried
out at a ﬂow-rate of 0.3 ml min−1 using either citrate buffer pH 8 (pH
gradient) or Glucose 5% (ammonium gradient) as the mobile phase
and 1 ml fractions were collected. The elution of OrG liposomes and
free OrG was monitored by measuring the ﬂuorescence with a four-
channel ﬂuorimeter Spex F1T11I (equipped with Peltier-cooled
photomultipliers and a 450 W xenon lamp) controlled by DM 3000
software (Spex Industries, Edison, USA). Fluorescence emission was
measured at 90°. Samples were maintained at 20 °C by a water bath
(Lauda RCS6, Lauda, Königshafen, Germany). OrG elution was
monitored at 555 nm after excitation at 488 nm, while liposomes
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Liposomes without external OrG were subjected to an emission scan
between 400 and 540 nm with excitation at 488 nm. Calibration was
done in the appropriate buffer as a function of pH which is directly
correlated with the ratio of the ﬂuorescence intensity measured at
504 nm and at 466 nm (Fig. 2).
2.4. DSC and X-ray sample preparation
Samples (about 20 mg of anhydrous lipids) were prepared by
dissolving and mixing the indicated lipids in ter-butanol at 60 °C to
obtain the desired composition. The sampleswere then freeze-dried at
Pb1 mbar and T=−35 °C and the lipid mixture obtained was
hydrated with water, citrate buffer (200 mM) pH 4 or ammonium
sulfate (155 mM) pH 4. Citrate buffer pH was increased with sodium
hydroxide (32%) and ammonium sulfate pH was decreased with
sulfuric acid (1 N). The ﬁnal concentration of lipids was 200 mg/ml.
The molar sterol concentrations were 0, 10 or 40 mol%. S12363 was
solubilized in citrate buffer or freeze-driedwith lipids before hydration
with water or ammonium sulfate. Chol-PEG was not added into the
membrane model in order to have well deﬁned X-ray patterns. These
suspensions were heated above the chain melting transition tempera-
ture of ESMand vortexed in order to ensure good sample homogeneity.
Using single use syringes equippedwith long needles, an aliquot of the
samples was then loaded into DSC hermetically sealed aluminumpans
(TA Instruments) and quartz capillaries (external diameter≤1.5 mm
and wall thickness=0.01 mm) (GLAS, Müller, Berlin, Germany). Low-
speed centrifugations (b1000 rpm) were used to concentrate the
lipidic phase down to the bottom of the capillary. The top of the
capillary was closed by a drop of melted parafﬁn to prevent water
evaporation. The suspensions phase separate into lipidic rich moiety
and clear water or buffer moiety, thus demonstrating full hydration.
Before analyses, DSC pans and capillaries were kept at 4 °C during at
least one night and at most one weak.
2.5. Differential scanning calorimetry
Differential scanning calorimetry (DSC) measurements were
performed in a Q1000 DSC, TA Instruments. Heating scans were run
from 10 °C to 60 °C at a heating rate of 2 °C/min. An empty
hermetically sealed aluminum pan was used as reference. The
calorimeter was calibrated using lauric acid as standard reference
sample (ΔH=178.3J/g, Tm=43.7 °C). Protocol of standardization by
lauric acid, which is a lipid with thermal properties close to those ofFig. 2. Calibration with Oregon green (1.5 mM) in citrate buffer 200 mM from pH 3
(bottom) to pH 12 (top). Citrate buffer pH was increased with NaOH 32%. OrG was
subjected to an emission scan between 400 and 540 nm with an excitation at 488 nm.
The pH is directly correlated with ratio of the ﬂuorescence intensity measured at
I2=504 nm and at I1=466 nm (insert).ESM, is described by Grabielle-Madelmont and Perron [21]. Data
analysis was performed using the TA Universal Analysis program. The
transition temperatures were taken at the onset of the transition
(Tonset), i.e., at the intercept of the tangent to the low-temperature side
of the thermal peakwith the baseline. The transition enthalpy changes
were obtained from the area under the peak and standardized by the
mass of the phospholipid. To calculate the area under the peak, the
baseline was formed by connecting the linear segments of the heat
capacity curve between the start and endpoint of the transition.
2.6. X-ray diffraction as a function of temperature
X-ray small and wide angle diffraction measurements were carried
out using a monochromatic focused X-ray beam (0.8×0.8 mm) on the
Austrian SAXSbeamline at ELETTRA, Trieste, Italy (H. Amenitsch, http://
www.ibr.oeaw.ac.at/beamline/index.html). For all of the experiments a
calorimeter sample holder (MICROCALIX) which allows X-ray diffrac-
tion patterns to be recorded as a function of temperature (XRDT),
developed by Keller et al. [22], was used. Simultaneous small-angle
(SAXS) and wide-angle (WAXS) X-ray scattering intensities of the
diffraction lines were recorded using two one dimensional position-
sensitive linear detectors (1024 channels, ﬁlled with argon–ethane
mixture). The calibration of the detectors was performed with crystal-
line β form of highly puriﬁed tristearin (repeat distance of 44.95±
0.05 Å at small angles and 4.59, 3.85, 3.70±0.01 Å at wide angles) [23].
X-ray data and DSC thermal measurements were synchronously
collected versus time by a National Instrument LabVIEW supported
data acquisition system (H. Amenitsch, HCI, Hecus X-ray Systems, Graz,
Austria). DSC-XRDT scanning rate were performed at 2 °C/min with a
time frame of 30 s (1 frame/°C) at either 8 keV or 16 keV.
2.7. Global analysis technique
Selected SAXS patterns in the gel and in the ﬂuid phase of ESM and
ESM/Chol mixtures water, in citrate buffer at pH 4 and in ammonium
sulfate solution at pH 4 were analyzed in terms of a global model
[24,25] using the program GAP (Global Analysis Program). The
analysis technique models the full q-range in the SAXS regime
including Bragg peaks and diffuse scattering (for recent review see
Pabst et al., 2006 [26]). The major advantage of this model is its ability
to retrieve structural information for all lamellar aggregation forms
including unilamellar, oligolamellar andmultilamellar vesicles using a
single description of the bilayer's electron density proﬁle. From the
analysis, we obtained the membrane thickness through the deﬁnition
dB=2(zH+2σH), where zH was the position of the headgroup
Gaussian modeling the electron density proﬁle and σH its width.
The bilayer separation was then simply given by dW=d−dB.
2.8. Cryo-transmission electron microscopy (c-TEM)
The cryogenic transmission microscopy investigations were per-
formedwith a Cryo-EFTEM LEO-Zeiss 912 at the “Service deMicroscopie
Electronique de l'Institut de Biologie Intégrative” (IFR 83 CNRS, Paris).
Liposomeswere prepared as described above andwere stored at 4 °C for
approximately 1 week prior to obtain the cryo-images. Samples (2–
5 μL) of both formulations (pH gradient and ammonium gradient) of
S12363 loaded and S12363 unloaded liposomes were deposited on a
Formvar/carbon coated copper grids. Excess liquid was thereafter
blotted away with ﬁlter paper. The samples were quickly vitriﬁed by
plunging them rapidly into liquid ethane bath cooled by liquid nitrogen
(LEICA EM CPC, Vienna, Austria). To prevent sample perturbation and
the formation of ice crystals, grids were kept below 108 K during both
the transfer and viewing procedures. All observations were made in
zero-loss bright-ﬁeld mode at an accelerating voltage of 120 kV. Note
that the two-dimensional projection of a closed liposomewill appear as
a circular object with enhanced contrast around the rim. This is due to
Fig. 4. Emission scans of the pH probe Oregon Green encapsulated in liposomes as a
function of time (λex=488 nm). The liposomes were prepared in citrate buffer pH 3. The
scan at day 0 (D0) was done just after external pH increase (see Materials and methods)
and after a gel exclusion chromatography was done to remove the external probe. Then,
liposome core pHwasmeasured 1, 2, 4, 10 and 28 days after this increase. In all cases a gel
exclusion chromatography was done before the emission scan. The internal pH is directly
correlated with the ratio of the ﬂuorescence intensity measured at wavelength 504 and
466 nm. The insert shows the evolution of the pH liposome core as a function of time.
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the edge.
2.9. Liposome stability and drug leakage
Liposome stability was evaluated by measuring the drug fraction
still encapsulated after 1month at+4 °C. To evaluate the drug release,
S12363-liposomes prepared by either pH gradient or ammonium
gradient were diluted 1:100 in PBS pH 7.4 and incubated at 37 °C
during 30 min. The encapsulated fraction was determined by
separating the entrapped drug from the free by a gel exclusion
chromatography through a Sephadex G75 column pre-equilibrated
PBS pH 7.4. S12363 release was followed by UV spectroscopy at
230 nm. The dosage of the encapsulated fraction was done by HPLC.
3. Results and discussion
3.1. Internal pH of liposomes
Liposomes were prepared either in citrate buffer pH 3 or in
ammonium sulfate pH 5.2. In the ﬁrst case the pH gradient was
formed by increasing the external pH of citrate buffer to 8. In
ammonium sulfate, an ammonium gradient was induced by removing
external salts (see Section 2). Noteworthy, in the absence of a gradient
between the external and internal core, it was impossible to load
signiﬁcant amount of S12363 into liposomes. The drug remained in
the ammonium sulfate solution in the external phase and only a weak
part of the drug interacted with the liposome membrane.
The mean diameter of the liposomes was measured by DLS and
yielded an average value of 170+/−10 nm in both cases. The liposomes
size and external pHwere stable over several months. Nevertheless the
inner pH of the liposomes at the moment of the gradient formation as
well as the gradient stability was unknown. Regarding the properties ofFig. 3. Lipophilic (A) and solubility (B) proﬁles of S12363 sulfate as a function of pH.the drug this parameter is the most important for the supramolecular
organization of the S12363-liposome. Indeed, S12363 is a weak base
highly soluble in acidic medium and poorly soluble in a neutral/basic
environment (Fig. 3). Theseproperties determine the afﬁnityof thedrug
substancewith the core or the liposomemembrane. Furthermore thepH
gradient persistence is correlated with the S12363-liposome stability.
For this purpose a pH probe (Oregon Green) has been encapsulated
into the vesicles (see Section 2). In the case of liposomes prepared in
citrate buffer, the internal pH was measured before the increase of the
external pH andwas found to be 3.1. This result was in accordancewith
the expected value of 3 and showed that Oregon Green was an
appropriate probe for pH determination in vesicle core. After external
pH increase, the internal pH reached a value of 4.6 (Fig. 4). This pHwas
then stable over a period of at least 28 days. In the case of liposomes
prepared in ammonium sulfate, the internal pH was measured just
after external salts removal (Fig. 5). The internal pH reached a value of
3.8 and was stable over a period of at least 20 days.
As these experiments were realized with unloaded liposomes,
S12363 was then solubilized in citrate buffer pH 4 and in ammonium
sulfate pH 4 at a concentration corresponding to the complete drug
solubilization in the aqueous core of the liposomes. To determine this
concentration, the trapped volume of vesicle preparations was
estimated as described previously [27,28], that is the internal volume,
Vint=5 μL/μmol of phospholipids for 170 nm liposomes. In the present
case a suspension of 8 mg/mL in lipids with an average FW of 1023.7
represents 7.815 μmol/mL of lipids and therefore a trapped volume in
the liposome suspension of 39.075 μL/mL. Since the drug concentra-
tion in the liposome suspension was 0.2 mg/mL, the estimated
concentration in the liposome core was 0.2/0.039=5.1 mg/mL.
In citrate buffer, no pH variation was seen in the presence of the
drug substance solubilized at 5.1 mg/mL. In ammonium sulfate the
drugwas not completely soluble at the same concentration and the pH
was increased from 4 to 6. This difference in drug solubility between
the two media was attributed to the buffer effect of the citrate buffer
and indicates that in the case of the ammonium gradient, part of the
drug could precipitate in the liposome interior.
3.2. Cryo-TEM
Since the formation of an insoluble precipitate in the liposome core
has shown previously to decrease the drug release in case of
Fig. 5. Emission scans of the pH probe Oregon Green encapsulated in liposomes as a
function of time (λex=488 nm). The liposomes were prepared in ammonium sulfate
pH 5.2. The scan at day 0 (D0) was done just after external salt removing (see Materials
and methods) and after a gel exclusion chromatography was done to remove the
external probe. Then, liposome core pH was measured 2, 6, 10 and 20 days after this
increase. In all cases a gel exclusion chromatographywas done before the emission scan.
The internal pH is directly correlated with the ratio of the ﬂuorescence intensity
measured at wavelength 504 and 466 nm. The insert shows the evolution of the pH
liposome core as a function of time.
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determine if a drug precipitation following S12363 loading occurred
in the case of NH3-gradient formulation. Liposome appearance was
determined by cryo-TEM with either a pH gradient or with a NH3-
gradient with and without S12363 encapsulated. Images are shown in
Fig. 6. Liposomes had spherical morphology and were mostly uniformFig. 6. Cryo-TEMmicrographs of liposomal formulations. Liposomes were prepared either by
of drug, (B and D) liposomal S12363 at a drug/lipid weight ratio of 1/35. The size bar reprin size. The interior of S12363-loaded liposomes exhibited the same
electron density compared with unloaded liposomes whatever the
loading process used. The drug precipitation in the liposome core
previously observed with doxorubicine [29], topotecan [30] or
suspected with vinca alkaloid [31] was not evidenced with S12363-
liposomes, maybe because of a lower drug-to-lipid ratio (between 5
and 10 fold) but more probably because S12363 was, at least partly,
embedded in the membrane.
3.3. Interactions between S12363 and liposome bilayer
DSC/X-ray measurements were performed to observe interactions
between the drug substance S12363 and the liposome bilayer. The
X-ray diffraction patterns were recorded at wide angles to get
information about the packing of the phospholipid hydrocarbon
chains and at low angles to obtain the long-range organization of the
lipid assemblies. To determine the impact on DSC-XRDT proﬁles of a
complete drug insertion into the membrane, S12363/bilayer interac-
tions were ﬁrst studied in puriﬁed water in which S12363 was not
soluble. Interactions between S12363 and the liposome bilayer were
then determined in the medium corresponding to the liposome core,
i.e., in citrate buffer or in ammonium sulfate at pH 4. Interactions
between S12363 and the lipid membrane have been determined
without cholesterol to get information about the behavior of the drug
substance in presence of ESM alone and with 10 and 40 mol% of Chol
to see the inﬂuence of Chol content on drug/bilayer interactions.
3.3.1. Drug/liposome bilayer interactions in water
Thermodynamic parameters of the main phase transition are
directly correlated with ESM chain melting. These parameters were
inﬂuenced by the insertion of the drug in ESM bilayers and variationspH-gradient (A and B) or by NH3-gradient (C and D). (A and C) Liposomes in the absence
esents 100 nm.
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drug concentration into the bilayer induced a decrease of both the
melting enthalpy (Fig. 7A) and the melting temperature (Fig. 7B). The
melting temperature was decreased from 39.3 °C without drug to
36.7 °C with the highest drug/ESMmolar ratio of 0.07, and themelting
enthalpy was decreased from 6.25 kcal/mol without drug to
4.35 kcal/mol with the drug/ESM ratio of 0.07 (drug/lipid weight
ratio=1/10). These results are consistent with a possible insertion of
S12363 into the bilayers. Moreover, the phase transition was wider
and a shoulder was observed on the high temperature side of the peak
in the presence of the drug (Fig. 8A, right side).
The melting transition was also identiﬁed by X-ray diffraction. The
wide angle diffraction patterns showed the existence of a transition
from an ordered to a disordered chain packing in the plane of the
bilayer. X-ray pattern at 20 °C of pure ESM bilayers hydrated with
puriﬁed water displayed a ripple lamellar gel phase Pβ′ with a
d-spacing of 65.4 Å and a broad wide angle line at 4.17 Å [32]. The
insertion of S12363 into the bilayers (molar ratio of 0.07) led to the
disappearance of the characteristic peak of the ripple phase at small
angles whereas the lamellar gel phase had a similar d-spacing
(Fig. 8A). The broad WAXS line at 4.17 Å showed that the hexagonal
chain packing was maintained. These observations suggested that a
gel phase with tilted hexagonally packed chains but without
modulation was formed in the presence of the drug. At 55 °C, the
lamellar d-spacing of the liquid crystal phase increased slightly
(+2.4 Å) due to an increase in dW (Fig. 8A and Table 1).
In the presence of 10 mol% of cholesterol, the thermodynamic
parameters with andwithout S12363weremarkedly different (Fig. 7).
In the presence of the drug (molar ratio of 0.07), themelting transition
waswider, the onset temperaturewas decreased and the presence of a
small second endotherm at higher temperature led to an offset
temperature close to those of ESM/Chol bilayers alone (Fig. 8, right
side). Themelting enthalpy was also decreased. The lamellar structure
was preserved whatever the temperature. Nevertheless, the drug
compound insertion induced a decrease of the d-spacing of the
lamellar gel phase Lβ from 73 Å to 71 Å and an increase in the d-Fig. 8. SWAXS diffraction patterns (left) at 20 °C (bottom) and 55 °C (top) of bilayers
hydrated with puriﬁed water. (A) ESM bilayers (plain curves) or ESM/S12363 bilayers (bold
curves) (B) ESM/Chol (90:10) bilayers (plain curves) or ESM/Chol/S12363 bilayers (bold
curves). (C) ESM/Chol (60:40) bilayers (plain curves) or ESM/Chol/S12363 bilayers (bold
curves).The right part shows corresponding DSC curves (scanning rate 2 °C/min).
Fig. 7. Fusion enthalpy (A) and temperature variation (B) of the chain melting transition
of ESM fully hydrated with water as a function of the drug/ESM molar ratio. (▪) ESM
bilayers without cholesterol; (●) ESM bilayers with 10 mol% of cholesterol.spacing of the liquid crystalline phase Lα from 63 Å to 66 Å. Electron
density proﬁles showed that these variations are due to changes of the
interbilayer water thickness (Table 1). Electron density proﬁles were
similar in the glycerol backbone-headgroup regions but differed
markedly throughout the region of the hydrocarbon tails (Fig. 9A and
B). This conﬁrmed that drug molecules were embedded in the bilayer.
In the presence of 40 mol% of cholesterol, the calorimetric signal
was too weak to be integrated and was well correlated with the
absence of WAXS peaks at all temperatures. The insertion of S12363
in the bilayer containing 40 mol% of Chol induced a weak increase of
the lamellar repeat period (0.5 Å) at 20 °C and no effect was seen at
55 °C (Fig. 8C).
3.3.2. Drug/liposome bilayer interactions in citrate buffer
The melting temperature, observed by DSC, occurred at lower
temperature in the presence of S12363 and the peak was wider
because of the occurrence of a shoulder on its high temperature side.
However, the fusion enthalpy was not decreased by the presence of
Table 1
Inﬂuence of S12363 on the bilayer thickness (dB) and the water layer thickness (dW) of
ESM and ESM/Chol (90:10) bilayers at 20 °C and 55 °C and fully hydrated with water,
citrate buffer pH4 or ammonium sulfate solution pH4.
Water Citrate buffer
pH4
Ammonium sulfate
pH4
ESM Without drug 20 °C dB – – –
dW – – –
55 °C dB 48.4 49.6 48.2
dW 14.3 16.2 29.0
S12363 20 °C dB – – –
dW – – –
55 °C dB 48.3 47.5 48.2
dW 15.9 26.1 32.5
ESM/Chol
90:10
Without drug 20 °C dB 54.1 56.6 55.7
dW 19.2 18.7 26.1
55 °C dB 53.5 51.3 49.5
dW 10 14.6 26.2
S12363 20 °C dB 56.3 56.6 54.7
dW 12.9 15.6 19.3
55 °C dB 48.1 49.5 48.9
dW 16.5 21.6 29.0
932 C. Chemin et al. / Biochimica et Biophysica Acta 1788 (2009) 926–935the drug, a slight increase was even seen as in DPPC/vinblastine
mixtures hydrated with ammonium sulfate 150 mM at pH 5.3 [16,33].
It is likely that S12363, which was protonated in citrate buffer, wasFig. 9.One-dimensional electrondensity proﬁle calculated from the small-angle scattering diffra
S12363 (plain curves) fully hydratedwith water (A, B), citrate buffer pH4 (C, D), and ammonium
characterize the position of the headgroup and 2σH is its width. The bilayer thickness dB is deﬁrather adsorbed at the lipid–water interface, interacting with the
headgroups, than embedded in the bilayer.
X-ray patterns supported this hypothesis. At 20 °C, ESM bilayer
exhibited a ripple lamellar gel phase, with a broad reﬂection at 4.17 Å,
as previously observed in water. This Pβ′ long-range organizationwas
not affected by the presence of the drug but the lamellar d-spacing
was increased from 68 Å to 74.7 Å and the ripple length was decreased
from 137 Å to113 Å (Fig. 10A). When temperature increased, the chain
melting was evidenced by the 4.17 Å-WAXS line vanishing. At 55 °C,
the lamellar d-spacing of the Lα phase was increased from 66.2 to
74.1 Å when the drug was added, due to an increase in dW.
In the presence of 10 mol% of cholesterol, S12363 induced a
decrease of Tonset but less than in water. The fusion enthalpy was
slightly higher in the presence of S12363, whereas the peak was
divided into two endotherms. The lamellar organization was not
affected by the drug presence (Fig. 10B). Nevertheless, lamellar
d-spacings were more inﬂuenced in citrate buffer than in water
since a decrease of 4 Åwas seen in the Lβ phase at 20 °C and an increase
of 5 Å was seen in the Lα phase at 55 °C. These variations were mainly
due to variation of the water layer thickness (Table 1). The shapes of
the electron density proﬁles seemed similar regardless the presence or
the absence of the drug andwhatever the temperature (Fig. 9C and D).
However, the difference of the electron density between the center ofctionpattern exhibitedbyESM/Chol (90:10) bilayerswithout S12363(dash curves) orwith
sulfate pH 4 (E, F) at 20 °C (A, C, E) and 55 °C (B, D, F). The Gaussians centered at+/−zH
ned by dB=2(zH+2σH), and the water layer dW is then given by dW=d−dB.
Fig. 10. SWAXS diffraction patterns (left) at 20 °C (bottom) and 55 °C (top) of bilayers
hydrated with citrate buffer pH 4. (A) ESM bilayers (plain curves) or ESM/S12363
bilayers (bold curves) (B) ESM/Chol (90:10) bilayers (plain curves) or ESM/Chol/
S12363 bilayers (bold curves). The right part shows correspondingDSC curves (scanning
rate 2 °C/min).
Fig. 11. SWAXS diffraction patterns (left) at 20 °C (bottom) and 55 °C (top) of bilayers
hydratedwith ammonium sulfate pH 4. (A) ESM bilayers (plain curves) or ESM/S12363
bilayers (bold curves) (B) ESM/Chol (90:10) bilayers (plain curves) or ESM/Chol/
S12363 bilayers (bold curves). (C) ESM/Chol (60:40) bilayers (plain curves) or ESM/
Chol/S12363 bilayers (bold curves). The right part shows corresponding DSC curves
(scanning rate 2 °C/min).
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increased a little in the presence of the drug. As the center of the
bilayer was supposed to have the same electron density in the
conditions studied, variations observed between the center of
the bilayer and the headgroup region should be due to modiﬁcation
of the headgroup electron density. This phenomenon conﬁrms that the
drug was mainly located at the interface and in the aqueous medium.
3.3.3. Drug/liposomes interactions in ammonium sulfate
The drug/bilayer interactions in ammonium sulfate appeared as
intermediate between those observed in water and in citrate buffer.
DSC measurements showed that Tonset was decreased and that the
peak was broader, as in other cases; the fusion enthalpy was weakly
decreased in the presence of the drug. As shown in a previous study,
ESM bilayers in ammonium sulfate exhibited a disordered lamellar
gel phase. The addition of S12363, like that of cholesterol, led to an
organized lamellar gel phase with a 4.17 Å-WAXS line (Fig. 11A). In
the liquid crystalline phase Lα, an increase of d-spacing (+3.8 Å)
was seen in the presence of the drug. The decrease of Tm and ΔH and
the effect on the lamellar gel phase organization showed that
S12363 interacted with the lipid membrane and could be embedded.
However, ΔH was not decreased as much as it was when the drug
was inserted into the bilayer hydrated with water. In ammonium
sulfate solution, as electrostatic interactions may exist between the
amino group of S12363 and the negatively charged phosphate group,
the drug inserted in the bilayer was, therefore, probably close to
the interface.In the presence of 10 mol% of cholesterol, the drug induced a
decrease of Tonset and the very broad peak was divided into two
endotherms whereas the fusion enthalpy was slightly decreased. The
Lβ organization was not affected by the drug but an important
decrease of the lamellar d-spacing was observed (−9 Å) (Fig. 11B).
Above the melting temperature, the lamellar d-spacing of the sample
containing the drug was closer to that of ESM/Chol bilayers alone
(+2 Å). Electron density proﬁles indicated that d-spacing changes
arised mainly from water layer thickness (Table 1). Moreover, they
also showed that at 20 °C, S12363 modiﬁed the difference of the
electron density between the center of the bilayer and the headgroups
Table 2
Encapsulation fraction of S12363 after 1 month at +4 °C and after S12363-liposomes
dilution in PBS pH 7.4 at 37 °C during 30 min.
Encapsulation fraction (%)
1 month 4 °C Dilution 1:100
pH gradient 94±6 67±4
Ammonium gradient 94±2 81±3
Results are the average of 3 experimental data.
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less marked at 55 °C.
In the presence of 40 mol% of cholesterol, the WAXS line as well as
the calorimetric transition vanished. At 20 °C, the drug did not
inﬂuence the membrane organization and the lamellar repeat period
was unchanged (Fig. 11C). At 55 °C, the same behavior was seen but
the drug presence favored the phase separation observed without the
drug.
In all the conditions studied, the DSC curve shape suggested that
the drug repartition into the membrane was not homogeneous.
However, X-ray patterns showed only one well deﬁned line corre-
sponding to one lamellar phase. It is rather considered that
inhomogeneities in the bilayer plan were formed, leading to S12363
rich domain speciﬁcally occurring in the presence of Chol (Chol-
S12363 rich domains). The association between Chol and the drug
could be steric (favored by complementary structures) and/or more
speciﬁc depending on the charge. In any case, Chol is supposed to
promote the drug insertion at least in the gel phase.
3.4. Liposome stability
Liposome stability was evaluated after 1 month at 4 °C. As shown
in Table 2 both formulations were stable over this period.
The drug leakage was then determined (37 °C; PBS) after drug
loading by either pH gradient or ammonium gradient. After 30 min,
67% (pH gradient) or 81% (ammonium gradient) of S12363 were still
encapsulated (Table 2). Thus, the drug release was faster when the
drug was encapsulated using a pH gradient rather than an ammonium
gradient. The presence of the drug into the bilayer did not lead to a
burst effect. On the contrary, drug–membrane interactions may favor
the drug retention into the liposomes. Thus, when the drug was
solubilized into the liposome core, it was released by a passive
diffusion through the lipid bilayer after liposome dilution. This
phenomenon was already observed in vinca-alcaloid loaded lipo-
somes using a pH gradient [31]. Moreover, it was previously shown
that the presence of sulfate into the liposome core could improve
Topotecan encapsulation, due to drug precipitation [30]. In the case of
S12363 encapsulated into liposomes by the ammonium gradient, a
slight precipitation, not seen by cTEM, could explain the limited
release observed. Furthermore, it has been previously shown that
ammonium sulfate adsorbed at ESM/Chol membrane surface [32].
Thus, sulfate is likely enhancing interactions between S12363 and the
bilayer, leading to a more stable formulation.
4. Conclusion
Interactions of the S12363 drug with ESM or ESM/Chol
membranes have been investigated in water, ammonium sulfate
solution and citrate buffer. It has been shown that, depending on the
aqueous medium, S12363 may be deeply embedded within the
bilayer, inserted in the vicinity of the polar headgroup or adsorbed at
the water–lipid interface. When the bilayers were hydrated with
water, insertion of the neutral S12363 was driven by hydrophobic
interaction. In ammonium sulfate, positively charged amino groups
of S12363 interacted with negatively charged phosphate groups, the
lipophilic groups being oriented towards the hydrophobic part of the
bilayer. When the membrane was melted, the lipid moleculesbecame less ordered, leading to a better insertion of the drug into
the bilayer. In citrate buffer, S12363 exhibited enhanced partitioning
at the interface, probably because of a higher charge. Moreover, DSC
studies have shown that the drug partitioning into the membrane
was inhomogeneous and led to the formation of drug-rich and drug-
poor domains. This effect was more marked when cholesterol was
added, especially in ammonium sulfate.
Regarding interactions evidenced between the drug and the
membrane bilayer, the supramolecular organization of the liposome
membrane was supposed to be affected by the drug. The drug
loading process and more speciﬁcally the formulation medium
signiﬁcantly inﬂuenced the drug/bilayer interactions. For both
formulations, the encapsulated drug partitioned between the
aqueous core and the bilayer. It was localized in the vicinity of the
ESM polar head groups and partially embedded into the sphingo-
myelin tails. In the case of ammonium sulfate gradient, the drug was
less soluble in the liposome core and drug/membrane interactions
were favored, leading to more drug insertion into the bilayer and
also to greatest stability of the liposome formulation. This study also
showed that X-ray diffraction coupled to DSC is a useful tool for
determining the localization of drugs into liposomes.
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